Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03214601 · ClinicalTrials.gov registry record · NA

Early Feasibility Study of the RelayBranch Thoracic Stent-Graft System

A NA study of Aortic Aneurysm and Aneurysm, Ruptured, sponsored by Bolton Medical.

Active
Registry status
NA
Development phase
30
Enrollment target
12
Study locations

NCT03214601: Active NA study of Aortic Aneurysm and Aneurysm, Ruptured, sponsored by Bolton Medical.

NCT03214601 is a NA study of Aortic Aneurysm and Aneurysm, Ruptured that is active but no longer recruiting, run by Bolton Medical. The registered enrollment target is 30 participants, below the 638-participant average among 14 other Aortic Aneurysm trials with a reported enrollment target (95% lower). The trial reports 12 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03214601, a NA study of Aortic Aneurysm and Aneurysm, Ruptured, is active but no longer recruiting, sponsored by Bolton Medical.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
30 participants
Enrollment target
12
Study locations

Study Summary

The purpose of this study is to conduct an early clinical evaluation of the Relay Branch System, which will provide initial insight into the clinical safety and function of the device. This Early Feasibility Study (EFS) will assess the safety and effectiveness of the device at the index procedure and at 30-day follow-up. The study will evaluate the delivery and deployment of the device, patency of branches and branch vessels, and exclusion of the aortic pathology. The data will help determine if modifications need to be made to the device, the procedural steps, operator technique, or the indications for use.

Primary Outcome

The primary safety outcome determined by the rate of MAEs, including * All-cause mortality * Disabling stroke: a Modified Rankin Score (mRS) of 2 or more at 90 days and an increase in at least one mRS category from an individual's pre-stroke baseline * Permanent Paralysis/Paraparesis * Spontaneous Myocardial Infarction according to the SCAI definition * Renal Failure * Procedural Blood Loss \>1,000mL

Interventions

  • DEVICE penetrating atherosclerotic ulcer, aorta branch cardiovascular implant

Study Locations (12)

Texas

  • Baylor College of Medicine - Houston
  • Baylor Scott and White Research Institute - Plano

California

  • University of Southern California - Los Angeles

Florida

  • University of Florida - Gainesville

Georgia

  • Emory University - Atlanta

Maryland

  • University of Maryland - Baltimore

Massachusetts

  • Massachusetts General Hospital - Boston

Missouri

  • Barnes Jewish Hospital at Washington University - St Louis

New York

  • Columbia University Medical Center - New York

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2017-12-04
Est. Completion 2028-08-31
Phase NA
Bolton Medical

10 total trials

What the registry record for NCT03214601 still lists

NCT03214601 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 638-participant average among 14 other Aortic Aneurysm trials with a reported enrollment target (95% lower).

The record links to 3 conditions, with Aortic Aneurysm appearing as the primary indexed condition, and to 1 intervention - of which penetrating atherosclerotic ulcer, aorta branch cardiovascular implant is the first listed.

NCT03214601 lists 12 locations in 11 states (Texas, California, Florida).

Frequently Asked Questions

What is clinical trial NCT03214601 about?

NCT03214601 is a clinical study titled "Early Feasibility Study of the RelayBranch Thoracic Stent-Graft System". The purpose of this study is to conduct an early clinical evaluation of the Relay Branch System, which will provide initial insight into the clinical safety and function of the device. This Early Feasibility Study (EFS) will assess the safety and effectiveness of the device at the index procedure a...

What is the current status of trial NCT03214601?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2017-12-04. Estimated completion is 2028-08-31.

What conditions does trial NCT03214601 study?

This clinical trial studies the following conditions: Aortic Aneurysm, Aneurysm, Ruptured, Thoracic Aorta Aneurysm.

What interventions are being tested in trial NCT03214601?

The interventions under investigation include: penetrating atherosclerotic ulcer, aorta branch cardiovascular implant (DEVICE).

Who is sponsoring clinical trial NCT03214601?

This trial is sponsored by Bolton Medical, which has 10 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03214601 being conducted?

This trial has 12 study locations across California, Florida, Georgia, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Aortic Aneurysm

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03214601's enrollment target sits among peer trials

30 11th of 14 higher than 4 of 14 other Aortic Aneurysm trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Aortic Aneurysm trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03214601, the US trial registry maintained by the National Library of Medicine. NCT03214601 (small enrollment · multi site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.